TY - JOUR
T1 - Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate- containing linker
AU - Cheng, Junping
AU - Persson, Mikael
AU - Tolmachev, Vladimir
AU - Siavaev, Igor
AU - Orlova, Anna
AU - Kairemo, Kalevi
AU - Anniko, Matti
N1 - Funding Information:
This project was supported by the Medical Faculty of the University of Uppsala, the Swedish Medical Research Council (project No. 17X-7305) and Cancerfonden, Sweden (project Nos. 4462-B01-02PAA and 3980-B00-04XBB). We thank Professor Guus van Dongen, who kindly donated cMAb U36 for use in this experiment. We also thank Professor Jörgen Carlsson for his valuable advice and Ms Veronica Eriksson and Ms Marika Nestor for their great help with cell culturing.
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2004
Y1 - 2004
N2 - Objective - High rates of local recurrence and distant metastases following surgery of high-grade head and neck squamous cell carcinoma (HNSCC) necessitate the use of adjuvant systemic treatment. Radioimmunotargeting might be a possible treatment modality in this case. The nuclear properties of 131I make it a suitable isotope for treatment of minimal residual disease and small metastases, but the conventional radioiodine label has poor cellular retention and its radiocatabolites accumulate in the thyroid. We attempted to overcome these problems by using closo-dodecaborate derivatives for attachment of radioiodine. Material and Methods - We investigated the feasibility of targeting an SCC25 HNSCC xenograft in vivo using a benzylisothiocyanate derivative of closo-dodecaborate (DABI) as radioiodine linker and the chimeric anti-CD44v6 antibody U36. 125I was used in biodistribution studies. Results - The use of DABI enabled tumor targeting and decreased the radioactivity uptake of the thyroid. Conclusion - Tumor localization of DABI-labeled U36 was similar to its para-iodobenzoate-labeled counterpart, presumably due to the strong dependence of targeting efficiency on tumor size.
AB - Objective - High rates of local recurrence and distant metastases following surgery of high-grade head and neck squamous cell carcinoma (HNSCC) necessitate the use of adjuvant systemic treatment. Radioimmunotargeting might be a possible treatment modality in this case. The nuclear properties of 131I make it a suitable isotope for treatment of minimal residual disease and small metastases, but the conventional radioiodine label has poor cellular retention and its radiocatabolites accumulate in the thyroid. We attempted to overcome these problems by using closo-dodecaborate derivatives for attachment of radioiodine. Material and Methods - We investigated the feasibility of targeting an SCC25 HNSCC xenograft in vivo using a benzylisothiocyanate derivative of closo-dodecaborate (DABI) as radioiodine linker and the chimeric anti-CD44v6 antibody U36. 125I was used in biodistribution studies. Results - The use of DABI enabled tumor targeting and decreased the radioactivity uptake of the thyroid. Conclusion - Tumor localization of DABI-labeled U36 was similar to its para-iodobenzoate-labeled counterpart, presumably due to the strong dependence of targeting efficiency on tumor size.
KW - I radionuclide labeling
KW - Chimeric antibody U36
KW - Head and neck
KW - Squamous cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=8744259798&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8744259798&partnerID=8YFLogxK
U2 - 10.1080/00016480410017891
DO - 10.1080/00016480410017891
M3 - Article
C2 - 15513553
AN - SCOPUS:8744259798
VL - 124
SP - 1078
EP - 1085
JO - Acta Oto-Laryngologica
JF - Acta Oto-Laryngologica
SN - 0001-6489
IS - 9
ER -